Riociguat for Sarcoidosis-Associated Pulmonary Hypertension
| Autor: | Rohit Gupta, Steven D. Nathan, Oksana A. Shlobin, Jeffrey I. Stewart, Robert P. Baughman, Franck Rahaghi, Elyse E. Lower, Joyce Zeigler, Peter J. Engel |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
Pulmonary and Respiratory Medicine
medicine.medical_specialty SF-36 business.industry Placebo-controlled study Critical Care and Intensive Care Medicine Placebo medicine.disease Riociguat Pulmonary hypertension FEV1/FVC ratio Internal medicine Clinical endpoint medicine Cardiology and Cardiovascular Medicine business Adverse effect medicine.drug |
| Zdroj: | Chest. 161:448-457 |
| ISSN: | 0012-3692 |
| DOI: | 10.1016/j.chest.2021.07.2162 |
| Popis: | Background Riociguat is effective in delaying the time to clinical worsening (TCW) in patients with groups 1 and 4 pulmonary hypertension. Research Question Is riociguat more effective than placebo in prolonging TCW in sarcoidosis-associated pulmonary hypertension (SAPH)? Study Design and Methods This was a double-blind placebo-controlled trial. Patients with SAPH confirmed by right heart catheterization were randomized 1:1 to riociguat or placebo. Patients underwent 6-min walk distance (6MWD) and spirometry testing every 8 weeks. The primary end point was TCW, which was defined by the time to the first of the following: (1) all-cause mortality, (2) need for hospitalization because of worsening cardiopulmonary status attributable to progression of disease, (3) > 50 m decrease in the 6MWD test, or (4) worsening of World Health Organization functional class. Results A total of 16 patients were randomized to riociguat (n = 8) or placebo (n = 8). No difference was found in pulmonary artery mean, pulmonary vascular resistance, initial 6MWD, or FVC between the two groups. Five of eight patients who received placebo met TCW criteria, whereas none of the patients who received riociguat experienced a qualifying event. By log-rank analysis, patients who received riociguat were in the study for a significantly longer period (χ 2 = 6.259; P = .0124). The 6MWD decreased in the placebo group (median, –55.9 m; range, –176.8 to 60 m), but rose in the riociguat group (median, +42.7 m; range, –7.5 to +91.4 m; P = .0149), with a placebo-corrected difference of 94 m (P 30-m improvement in 6MWD (P > .05). No significant adverse events associated with riociguat occurred. Interpretation Over the 1 year of the study, riociguat was effective in preventing clinical worsening and improving exercise capacity in patients with SAPH. Trial Registry ClinicalTrials.gov ; No.: NCT02625558 ; URL: www.clinicaltrials.gov |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|